Rep. Robert Bresnahan, Jr. Sells Amgen Inc. (NASDAQ:AMGN) Stock

Representative Robert Bresnahan, Jr. (R-Pennsylvania) recently sold shares of Amgen Inc. NASDAQ: AMGN. In a filing disclosed on May 08th, the Representative disclosed that they had sold between $1,001 and $15,000 in Amgen stock on April 8th. The trade occurred in the Representative's "JP MORGAN BROKERAGE ACCOUNT" account.

Representative Robert Bresnahan, Jr. also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Meta Platforms NASDAQ: META on 4/17/2025.
• Sold $1,001 - $15,000 in shares of Meta Platforms NASDAQ: META on 4/16/2025.
• Sold $1,001 - $15,000 in shares of Western Digital NASDAQ: WDC on 4/11/2025.
• Purchased $1,001 - $15,000 in shares of Alphabet NASDAQ: GOOG on 4/11/2025.
• Purchased $1,001 - $15,000 in shares of Texas Instruments NASDAQ: TXN on 4/11/2025.
• Purchased $1,001 - $15,000 in shares of NVIDIA NASDAQ: NVDA on 4/11/2025.
• Sold $1,001 - $15,000 in shares of Western Digital NASDAQ: WDC on 4/10/2025.
• Sold $1,001 - $15,000 in shares of DexCom NASDAQ: DXCM on 4/8/2025.
• Sold $1,001 - $15,000 in shares of Invesco NYSE: IVZ on 4/8/2025.
• Sold $1,001 - $15,000 in shares of Generac NYSE: GNRC on 4/8/2025.

Amgen Price Performance

Shares of AMGN stock traded down $4.46 during mid-day trading on Tuesday, hitting $270.30. 550,847 shares of the stock were exchanged, compared to its average volume of 3,137,049. Amgen Inc. has a 52-week low of $253.30 and a 52-week high of $346.85. The company has a quick ratio of 0.95, a current ratio of 1.26 and a debt-to-equity ratio of 9.62. The company has a market cap of $145.34 billion, a PE ratio of 35.80, a price-to-earnings-growth ratio of 2.63 and a beta of 0.51. The firm has a fifty day moving average of $295.24 and a 200 day moving average of $289.21.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The medical research company reported $4.90 EPS for the quarter, beating analysts' consensus estimates of $4.18 by $0.72. Amgen had a return on equity of 176.32% and a net margin of 12.24%. The business had revenue of $8.15 billion during the quarter, compared to analysts' expectations of $8.05 billion. During the same period in the previous year, the business earned $3.96 earnings per share. The business's revenue was up 9.4% compared to the same quarter last year. Research analysts anticipate that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Friday, May 16th will be issued a $2.38 dividend. The ex-dividend date is Friday, May 16th. This represents a $9.52 dividend on an annualized basis and a yield of 3.52%. Amgen's payout ratio is 86.86%.

Insider Buying and Selling

In other news, EVP David M. Reese sold 25,225 shares of the company's stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $304.44, for a total value of $7,679,499.00. Following the completion of the sale, the executive vice president now directly owns 36,922 shares of the company's stock, valued at approximately $11,240,533.68. This represents a 40.59% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.76% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several research firms have recently weighed in on AMGN. Citigroup restated a "neutral" rating on shares of Amgen in a research report on Wednesday, February 5th. Morgan Stanley reiterated an "equal weight" rating on shares of Amgen in a report on Friday, May 2nd. Royal Bank of Canada reduced their target price on shares of Amgen from $324.00 to $320.00 and set an "outperform" rating on the stock in a research note on Friday, May 2nd. StockNews.com lowered Amgen from a "strong-buy" rating to a "buy" rating in a research report on Saturday. Finally, Piper Sandler raised their price objective on Amgen from $310.00 to $329.00 and gave the stock an "overweight" rating in a research report on Monday, February 10th. Two analysts have rated the stock with a sell rating, eleven have given a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $310.23.

Hedge Funds Weigh In On Amgen

A number of institutional investors and hedge funds have recently modified their holdings of AMGN. E Fund Management Co. Ltd. lifted its holdings in Amgen by 56.2% during the 1st quarter. E Fund Management Co. Ltd. now owns 19,338 shares of the medical research company's stock worth $6,025,000 after buying an additional 6,956 shares during the last quarter. Tokio Marine Asset Management Co. Ltd. increased its stake in Amgen by 6.3% in the first quarter. Tokio Marine Asset Management Co. Ltd. now owns 16,718 shares of the medical research company's stock valued at $5,208,000 after purchasing an additional 990 shares during the last quarter. Caitong International Asset Management Co. Ltd raised its holdings in Amgen by 58.8% during the first quarter. Caitong International Asset Management Co. Ltd now owns 791 shares of the medical research company's stock worth $246,000 after purchasing an additional 293 shares in the last quarter. National Pension Service lifted its position in shares of Amgen by 6.4% during the 1st quarter. National Pension Service now owns 1,163,689 shares of the medical research company's stock worth $362,547,000 after buying an additional 70,126 shares during the last quarter. Finally, Klingman & Associates LLC boosted its holdings in shares of Amgen by 13.8% in the 1st quarter. Klingman & Associates LLC now owns 1,350 shares of the medical research company's stock valued at $421,000 after buying an additional 164 shares in the last quarter. Institutional investors and hedge funds own 76.50% of the company's stock.

About Representative Bresnahan

Rob Bresnahan Jr. (Republican Party) is a member of the U.S. House, representing Pennsylvania's 8th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Bresnahan (Republican Party) is running for re-election to the U.S. House to represent Pennsylvania's 8th Congressional District. He declared candidacy for the 2026 election. Rob Bresnahan Jr. was born in Kingston, Pennsylvania. He earned a B.S. in business administration, management and operations from the University of Scranton in 2012. His career experience includes working as the chief financial officer and CEO of a family business, an electrical contracting company.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.